Jessica C Sieren,Dawn Quelle,David K Meyerholz et al.
Jessica C Sieren et al.
Large-animal cancer models are needed to advance the development of innovative and clinically applicable tumor diagnostic, therapeutic, and monitoring technologies. We developed a genetically modified porcine model of cancer based on a TP53...
Divide and rule: The role of ubiquitination in inactivation of the ERK5-MAPK cascade [0.03%]
分而治之：泛素化在ERK5-MAPK级联失活中的作用
Katharina Schulenburg,Gabor Glatz,Attila Remenyi et al.
Katharina Schulenburg et al.
Recently, we revealed that ubiquitination of MEKK2 and MEKK3 by inhibitor of apoptosis proteins (IAPs) directly disrupts MEK5/ERK5 interaction and subsequently attenuates ERK5 activation. In addition, loss of XIAP promotes human myogenic di...
David J Cantor,Gregory David
David J Cantor
Cellular senescence is classically considered a tumor suppressive mechanism. In addition to having stably exited the cell cycle, senescent cells secrete inflammatory factors. We recently demonstrated that senescence correlates with accelera...
Verónica Rivas,Laura Nogués,Clara Reglero et al.
Verónica Rivas et al.
Downregulation of G protein-coupled receptor kinase 2 (GRK2) in endothelial cells has recently been identified as a relevant event in the tumoral angiogenic switch. Based on the effects of altering GRK2 dosage in cell and animal models, thi...
Triple threat treatment: Exploiting the dependence receptor properties of metabotropic glutamate receptor 1 against melanoma [0.03%]
三管齐下的治疗方法：利用代谢型谷氨酸受体1对抗黑色素瘤的依赖性受体属性
Tara Gelb,Hannah A Hathaway,Jarda T Wroblewski
Tara Gelb
Melanoma cells that express metabotropic glutamate 1 (mGlu1) receptors depend on glutamate for their survival and proliferation. The dependence receptor properties of mGlu1 allow us to propose and justify three promising approaches for mela...
Improving VEGF-targeted therapies through inhibition of COX-2/PGE2 signaling [0.03%]
通过抑制COX-2 / PGE2信号改善VEGF靶向疗法
Lihong Xu,Brad St Croix
Lihong Xu
Antiangiogenic agents targeting the vascular endothelial growth factor A (VEGFA) pathway play an important role in current cancer treatment modalities but are limited by alternative angiogenesis mechanisms. Recent studies suggest that enhan...
J C Bourdon
J C Bourdon
Although p53 defines cellular responses to cancer treatment it is not clear how p53 can be used to control cell fate outcome. Data demonstrate that so-called p53 does not exist as a single protein, but is in fact a group of p53 protein isof...
Targeting tumor cell metabolism via the mevalonate pathway: Two hits are better than one [0.03%]
靶向肿瘤细胞代谢的甲羟戊酸途径：双重攻击比单一攻击更有效
Aleksandra Pandyra,Linda Z Penn
Aleksandra Pandyra
Statins are promising anticancer agents that target the mevalonate pathway. Tumor cells are sensitive to depletion of mevalonate-derived products but this activity triggers a homeostatic feedback loop that blunts statin efficacy. We showed ...
Timothy R Hercus,Sophie E Broughton,Matthew P Hardy et al.
Timothy R Hercus et al.
CSL362 is a humanized interleukin-3 (IL-3)-neutralizing monoclonal antibody with enhanced effector function that binds the α subunit of the IL-3 receptor (IL3Rα). The crystal structure of an IL3Rα:CSL362 complex shows that IL3Rα adopts ...
Hideki Izumi,Yasuhiko Kaneko
Hideki Izumi
Asymmetric cell division (ACD) is a characteristic of cancer stem cells, which exhibit high malignant potential. However, the cellular mechanisms that regulate symmetric (self-renewal) and asymmetric cell divisions are mostly unknown. Using...